IL6 and nosocomial infection: Although the risk of nosocomial infection was not high in clinical trials in COVID-19 (<1% in both REMAP-CAP and RECOVERY; [9,10]), careful evaluation of the potential harms of IL6RA in a population with infection will be required in trial design, given the double-edged nature of IL6 inhibition.